UK NICE guidance on AMD will not give advice on Avastin
This article was originally published in SRA
The UK's National Institute for Health and Care Excellence (NICE) has begun consulting on a draft guideline on treatments for age-related macular degeneration covering all therapies that are currently being used for wet AMD, including Novartis's Lucentis (ranibizumab), Roche's Avastin (bevacizumab), and Bayer's Eylea (aflibercept)1,2.
You may also be interested in...
A project is about to begin to understand the factors that influence marketing decisions in the various EU member states.
EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's COVID-19 vaccine.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.